Heterocyclyl-3-sulfonylazaindole or-azaindazole derivatives as 5-hydroxytryptamine-6 ligands
US7259165B2 · kind B2 · utility
55Cited by
1References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 13, 2004 |
| Grant date | Aug 21, 2007 |
| Priority date | — |
| Expiry date | Aug 11, 2025 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the 5-HT6 receptor.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.